{"id":"https://openalex.org/W2013221641","doi":"https://doi.org/10.2174/156720505774330564","title":"Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects","display_name":"Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects","publication_year":2005,"publication_date":"2005-09-30","ids":{"openalex":"https://openalex.org/W2013221641","doi":"https://doi.org/10.2174/156720505774330564","mag":"2013221641","pmid":"https://pubmed.ncbi.nlm.nih.gov/16248851"},"language":"en","primary_location":{"id":"doi:10.2174/156720505774330564","doi":"https://doi.org/10.2174/156720505774330564","is_oa":false,"landing_page_url":"https://doi.org/10.2174/156720505774330564","pdf_url":null,"source":{"id":"https://openalex.org/S188438558","display_name":"Current Alzheimer Research","issn_l":"1567-2050","issn":["1567-2050","1875-5828"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056649584","display_name":"Nigel H. Greig","orcid":"https://orcid.org/0000-0002-3032-1468","observed_orcids":["https://orcid.org/0000-0002-3032-1468"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210136897","display_name":"National Institute on Aging","ror":"https://ror.org/049v75w11","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210136897"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nigel Greig","raw_affiliation_strings":["Drug Design & Development Section, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224 USA. Greign@grc.nia.nih.gov"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Design & Development Section, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224 USA. Greign@grc.nia.nih.gov","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210136897"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110594455","display_name":"Jon Ruckle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jon Ruckle","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031875721","display_name":"Patrick Comer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick Comer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000973850","display_name":"Lidia Alfaro Brownell","orcid":"https://orcid.org/0000-0002-5328-0152","observed_orcids":["https://orcid.org/0000-0002-5328-0152"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lidia Brownell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110898328","display_name":"Harold W. Holloway","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Harold Holloway","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005897972","display_name":"Douglas R. Flanagan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas Flanagan Jr.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Craig Canfield","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Craig Canfield","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5108345071","display_name":"Robert Burford","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Burford","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.5149,"has_fulltext":false,"cited_by_count":37,"citation_normalized_percentile":{"value":0.82150895,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"2","issue":"4","first_page":"483","last_page":"492"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10875","display_name":"Pesticide Exposure and Toxicity","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acetylcholinesterase-inhibitors","display_name":"acetylcholinesterase inhibitors","score":0.9570000171661377},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9120000004768372},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9919999837875366},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7369999885559082},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.5989999771118164},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7459999918937683},{"id":"https://openalex.org/keywords/plasma-concentration","display_name":"plasma concentration","score":0.36000001430511475},{"id":"https://openalex.org/keywords/pk-pd-relationship","display_name":"PK/PD relationship","score":0.7059999704360962}],"concepts":[{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.7426758408546448},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.731606125831604},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7071770429611206},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6399470567703247},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.608750581741333},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6008314490318298},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4895664155483246},{"id":"https://openalex.org/C2779059548","wikidata":"https://www.wikidata.org/wiki/Q383701","display_name":"Ach\u00e9","level":4,"score":0.4747115671634674},{"id":"https://openalex.org/C2778816929","wikidata":"https://www.wikidata.org/wiki/Q22676679","display_name":"Acetylcholinesterase","level":3,"score":0.4701041579246521},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.4315928518772125},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3469997048377991},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1776382029056549},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0721023678779602},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.06088244915008545}],"mesh":[{"descriptor_ui":"D000110","descriptor_name":"Acetylcholinesterase","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004912","descriptor_name":"Erythrocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004912","descriptor_name":"Erythrocytes","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010830","descriptor_name":"Physostigmine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010830","descriptor_name":"Physostigmine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010830","descriptor_name":"Physostigmine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/156720505774330564","doi":"https://doi.org/10.2174/156720505774330564","is_oa":false,"landing_page_url":"https://doi.org/10.2174/156720505774330564","pdf_url":null,"source":{"id":"https://openalex.org/S188438558","display_name":"Current Alzheimer Research","issn_l":"1567-2050","issn":["1567-2050","1875-5828"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer Research","raw_type":"journal-article"},{"id":"pmid:16248851","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16248851","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer research","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2005027072","https://openalex.org/W4284679245","https://openalex.org/W2155604829","https://openalex.org/W3021470512","https://openalex.org/W2056604025","https://openalex.org/W4321165409","https://openalex.org/W2951750024","https://openalex.org/W2067430705","https://openalex.org/W2145423346","https://openalex.org/W2026453450"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,15,45,76,121,163,190,198],"safety,":[4],"maximum":[5],"tolerated":[6,172],"dose":[7,179,201],"(MTD),":[8],"pharmacokinetics":[9],"(PK),":[10],"and":[11,39,58,81,93,120,159,170,192],"pharmacodynamics":[12],"(PD)":[13],"of":[14,33,85,95,108,114,126,140,148,180,194],"acetyl-selective":[16],"anticholinesterase,":[17],"phenserine":[18,34,86,96,109,157],"tartrate,":[19],"in":[20,162,189],"healthy":[21,26],"elderly":[22,27],"subjects.":[23],"METHODS:":[24],"32":[25],"volunteers":[28],"received":[29],"single":[30,177],"oral":[31,178],"doses":[32],"tartrate":[35,87,110,167],"(5-20":[36],"mg).":[37],"Physical":[38],"vital":[40],"signs":[41],"were":[42,50,60,79,102],"monitored":[43],"over":[44],"ensuing":[46],"24":[47],"hours.":[48,146],"Analyses":[49],"performed":[51],"on":[52],"plasma":[53,156],"samples":[54],"to":[55],"determine":[56],"PK,":[57],"PD":[59],"assessed":[61],"using":[62],"an":[63],"erythrocyte":[64],"acetylcholinesterase":[65],"(AChE)":[66],"inhibition":[67,124,142,161],"assay.":[68],"RESULTS:":[69],"No":[70],"serious":[71],"adverse":[72],"events":[73],"(AEs)":[74],"occurred;":[75],"most":[77],"common":[78],"headache":[80],"vomiting.":[82],"The":[83,91,138],"MTD":[84],"was":[88,128,144,168],"10":[89,106,185],"mg.":[90,186],"Cmax":[92,113],"AUC(0-24)":[94],"increased":[97],"with":[98],"dose,":[99],"but":[100],"neither":[101],"dose-proportional.":[103],"Subjects":[104],"receiving":[105],"mg":[107,183,200],"had":[111],"a":[112,152,176],"1.95":[115],"ng/mL":[116],"at":[117,132,197],"1.5":[118],"hours,":[119],"mean":[122],"peak":[123],"(Imax)":[125],"AChE":[127,141,160],"26%":[129],"(range:":[130],"18-34%)":[131],"1.75":[133],"hours":[134],"(tImax)":[135],"following":[136],"dosing.":[137],"half-life":[139],"(tI1/2)":[143],"11":[145],"Evaluation":[147],"PK/PD":[149],"relationships":[150],"suggested":[151],"linear":[153],"correlation":[154],"between":[155],"concentration":[158],"blood.":[164],"CONCLUSIONS:":[165],"Phenserine":[166],"safe":[169],"well":[171],"when":[173],"administered":[174],"as":[175],"either":[181],"5":[182],"or":[184],"An":[187],"increase":[188],"severity":[191],"frequency":[193],"AEs":[195],"occurred":[196],"20":[199],"level.":[202]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}